Premarket Tobacco Product Application: Contents, Review, and Penalties

A Premarket Tobacco Product Application, or PMTA, is the submission a manufacturer files with the U.S. Food and Drug Administration to get authorization to sell a new tobacco product in the United States. Federal law requires this authorization before the product can reach store shelves, and the applicant must show through scientific evidence that marketing the product is appropriate for the protection of public health.¹

Which Products Need One

Section 910 of the Federal Food, Drug, and Cosmetic Act treats a product as “new” in two situations. The first is any tobacco product that was not commercially marketed in the United States as of February 15, 2007. The second is any modification to a product that was on the market by that date, including changes to design, components, ingredients, nicotine content or delivery, flavorings, or additives.¹ Small tweaks count. A modified version of an existing product is a new product in the FDA’s eyes and needs its own authorization.

The 2016 Deeming Rule brought e-cigarettes, vape pens, e-liquids, cigars, pipe tobacco, hookah tobacco, and other products meeting the statutory definition under the same premarket framework that already applied to cigarettes and smokeless tobacco.² A March 2022 amendment closed another gap: FDA authority now covers products containing nicotine from any source, including synthetic nicotine, which some manufacturers had previously used to sidestep premarket review.³

The PMTA is not the only path to market. A product that closely resembles one sold before February 15, 2007 may qualify for the Substantial Equivalence pathway, where the applicant shows the new product has the same characteristics as a predicate product or that any differences do not raise different questions of public health.⁴ A narrower SE Exemption covers minor modifications the FDA agrees can bypass even the Substantial Equivalence report. Genuinely novel products have no shortcut and must go through the full PMTA.

What the Application Must Contain

The application has to make a scientific case that the product’s benefit to the population as a whole outweighs the risks to non-users. That case is built out of several distinct bodies of evidence, and gaps in any of them will show.

Scientific and Health Data

Applicants must submit full reports of all investigations, both favorable and unfavorable, that are published, known to, or should reasonably be known to the applicant.⁵ “All” is the operative word. Selectively including favorable data while leaving out inconvenient findings is the kind of thing that gets an application denied.

The submission must include a toxicological profile covering genotoxicity, carcinogenicity, reproductive toxicity, immunotoxicity, and acute and chronic toxicity of the product relative to other tobacco products on the market.⁵ The comparative framing matters. The FDA is not asking whether the product is safe in absolute terms; it is asking how the product’s risks compare to what consumers already use. Applicants also have to test for the constituents on the FDA’s established list of Harmful and Potentially Harmful Constituents.

Behavioral and Population Evidence

Chemistry alone is not enough. The FDA also wants evidence on how the product will affect human behavior:

How likely people who have never used tobacco, particularly young people, are to start using the product
Whether current tobacco users who might otherwise quit will instead switch to or continue using this product
Whether consumers will use it alongside traditional cigarettes rather than as a replacement, raising their total exposure

Each of these questions needs its own body of evidence.⁵ Consumer perception studies matter here too, since packaging, marketing, and design shape what people believe about the product’s risks and whether non-users are tempted to try it.

Technical and Manufacturing Information

The application must include a complete statement of all components, parts, materials, ingredients, additives, constituents, and properties of the product, along with its principle of operation.⁵ For an electronic device, that means documenting the hardware in detail, not just the e-liquid formulation.

The applicant also has to describe the methods, facilities, and controls used for design, manufacturing, packing, and storage in enough detail to show the product consistently meets its specifications. Specimens of all proposed labeling go in as well: labels, inserts, instructions, and any other material that will appear with the retail product. After acceptance, the FDA may also request physical product samples.⁵

Environmental Assessment

Under the National Environmental Policy Act, most PMTAs must include an environmental assessment or a claim of categorical exclusion. The assessment is a concise document analyzing environmental impacts from use and disposal and alternatives that would pose less risk. Failing to submit an adequate assessment when one is required gives the FDA grounds to refuse to file the application.⁶ Some FDA tobacco actions qualify for categorical exclusions, but a PMTA seeking a new marketing authorization generally does not.

How to Submit

Manufacturers file the completed application electronically through the CTP Portal NextGen, a web-based system operated by the FDA’s Center for Tobacco Products. As of January 2, 2026, all submissions must use Form FDA 4057 as the cover sheet. An outdated form or one filled out incorrectly can lead the FDA to refuse to accept the application outright.⁷

The application itself has to include a comprehensive index, a table of contents, and be well-organized, legible, and written in English. Translated documents require the original-language version, a signed certification of accuracy, and the translator’s qualifications. The whole package must be in an electronic format the FDA can process, read, review, and archive.⁸

How the FDA Reviews It

Once submitted, the application moves through a structured sequence before the FDA issues a decision.

Acceptance Review

The first gate is administrative. The FDA may refuse to accept an application that does not comply with formatting requirements, does not contain the information required by regulation, or does not pertain to a tobacco product subject to FDA authority.⁹ Failure at this stage produces a Refuse to Accept letter, and the process stops until the applicant fixes the deficiencies and resubmits.¹⁰

Filing Review

Applications that pass acceptance move to a filing review, where the FDA looks at whether the submission contains enough substantive information to permit a meaningful scientific evaluation. An application that has all the right sections but thin evidence in them receives a Refuse to File letter here.¹⁰

Substantive Review

Once an application is officially filed, FDA scientists dig into the data. The statutory deadline for completing this review is 180 days from receipt of a filed application.¹¹ The FDA can pause the clock if the applicant prevents the agency from scheduling or conducting a necessary facility inspection, for however long is needed to complete it. The volume of applications filed after the Deeming Rule has stretched real-world timelines well beyond 180 days for many applicants.

The Decision

At the end of the review, the FDA issues one of two orders. A Marketing Granted Order authorizes the product for sale under specific conditions and takes effect on the date it is issued.¹² A Marketing Denial Order means the FDA found the product failed to demonstrate it is appropriate for the protection of public health.¹⁰

What Happens After Authorization

A Marketing Granted Order comes with ongoing obligations. Failing to meet them can lead to the order being withdrawn or suspended.

Applicants must submit periodic reports to the Center for Tobacco Products within 60 calendar days of each reporting date specified in their marketing order. These reports cover changes to manufacturing processes, ongoing and completed studies, sales and distribution data by region and demographic, and an assessment of how the product continues to be appropriate for public health. They also include specimens of all labeling and advertising, details of paid media plans and dollar amounts, targeting data, actions taken to keep advertising away from minors, and any use of influencers or brand ambassadors.¹³

Any serious and unexpected adverse experience associated with the product must be reported to the FDA’s Office of Science within 15 calendar days of the applicant learning about it, through the HHS Safety Reporting Portal. If a manufacturing change results in a product outside the scope of the original order, the applicant may need to submit an entirely new PMTA.¹³

Federal rules also restrict how authorized products can be marketed. Manufacturers cannot sponsor athletic, musical, or cultural events using brand names or logos associated with cigarettes or smokeless tobacco. Free samples are prohibited for all tobacco products, with a narrow exception for smokeless tobacco distributed in qualified adult-only facilities. Advertisements must carry required health warning statements occupying at least 20 percent of the ad area, printed in specified fonts and formats.¹⁴

If the Application Is Denied

A denial is not necessarily permanent. The most common next step is a revised PMTA that addresses the specific deficiencies the FDA identified. Denial letters typically explain the evidentiary gaps or scientific shortcomings that led to the decision, so they double as a roadmap for what a successful resubmission needs.

Manufacturers may also seek judicial review in federal court. Several tobacco and e-cigarette companies have challenged Marketing Denial Orders through the federal appeals courts with mixed results. Courts evaluate whether the FDA’s decision was supported by substantial evidence and followed proper procedure, and they generally defer to the agency’s scientific expertise. Some challenges have resulted in orders being vacated and remanded, but the process is expensive and slow.

Penalties for Selling Without Authorization

Selling a tobacco product without a valid marketing authorization carries real financial consequences. The FDA enforces compliance through civil money penalties, adjusted annually for inflation. As of January 2026, the maximum penalty is $21,903 per violation under the standard tier and up to $365,050 per violation for more severe infractions.¹⁵

1
Office of the Law Revision Counsel. 21 USC 387j – Application for Review of Certain Tobacco Products
2
Federal Register. Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act
3
U.S. Food and Drug Administration. New Law Clarifies FDA Authority to Regulate Synthetic Nicotine
4
U.S. Food and Drug Administration. Substantial Equivalence
5
eCFR. 21 CFR Part 1114 – Premarket Tobacco Product Applications
6
eCFR. 21 CFR Part 25 – Environmental Impact Considerations
7
U.S. Food and Drug Administration. Electronic Submissions for Tobacco Products
8
U.S. Food and Drug Administration. Preparing and Submitting a Premarket Tobacco Product Application
9
eCFR. 21 CFR 1114.27 – Review Procedure
10
U.S. Food and Drug Administration. Premarket Tobacco Product Applications
11
eCFR. 21 CFR 1114.27 – Review Procedure
12
eCFR. 21 CFR Part 1114 Subpart C – FDA Review
13
eCFR. 21 CFR 1114.41 – Reporting Requirements
14
U.S. Food and Drug Administration. Advertising and Promotion
15
Federal Register. Annual Civil Monetary Penalties Inflation Adjustment